Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Skanska AB ( ($SE:SKA.B) ) has issued an update.
Skanska has secured an additional contract worth USD 116 million with the University of Virginia for the construction of the Paul and Diane Manning Institute of Biotechnology at Fontaine Research Park in Charlottesville, Virginia. This state-of-the-art facility, expected to be completed by the fourth quarter of 2027, will feature modular laboratory spaces and areas for collaboration among researchers and biotechnology companies, enhancing Skanska’s position in the biotechnology construction sector.
The most recent analyst rating on ($SE:SKA.B) stock is a Buy with a SEK254.00 price target. To see the full list of analyst forecasts on Skanska AB stock, see the SE:SKA.B Stock Forecast page.
More about Skanska AB
Skanska Group is one of the world’s largest construction and project development companies, with 2024 revenue totaling SEK 177 billion. Operating across select markets in the Nordics, Europe, and the USA, Skanska focuses on creating innovative and sustainable solutions that support healthy living. The company leverages its expertise and foresight to shape the way people live, work, and connect.
YTD Price Performance: 7.93%
Average Trading Volume: 617,932
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK99.18B
Find detailed analytics on SKA.B stock on TipRanks’ Stock Analysis page.